Management and monitoring are essential elements of the treatment journey

Prior to infusion, ensure patients have baseline tests for liver function,a creatinine, complete blood count (including hemoglobin and platelet count), and troponin-I.1

After infusion, continue to monitor liver function, platelet count,b and troponin-I as described in the Prescribing Information. See the recommended schedule of assessments in the accompanying chart.1

W=week.

aLiver function assessment includes a clinical exam and laboratory testing of hepatic aminotransferases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]), total bilirubin, and prothrombin time. Monitor liver function for 3 months or longer until results are unremarkable (normal clinical exam, total bilirubin, and prothrombin results, and ALT and AST levels below 2 × ULN).

bMonitor platelet counts as well as signs and symptoms of TMA, such as hypertension, increased bruising, seizures, or decreased urine output.

cMonitor platelet counts and troponin-I levels for 3 months or longer until they return to baseline.

=monitoring performed

aLiver function assessment includes a clinical exam and laboratory testing of hepatic aminotransferases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]), total bilirubin, and prothrombin time. Monitor liver function for 3 months or longer until results are unremarkable (normal clinical exam, total bilirubin, and prothrombin results, and ALT and AST levels below 2 × ULN).

bMonitor platelet counts as well as signs and symptoms of TMA, such as hypertension, increased bruising, seizures, or decreased urine output.

cMonitor platelet counts and troponin-I levels for 3 months or longer until they return to baseline.

Treat with systemic corticosteroids

To help manage a possible increase in liver aminotransferases, treat all patients with systemic corticosteroids before treatment and continue regimen after treatment1

The recommended treatment regimen is detailed in the Prescribing Information and in the accompanying chart.

If oral corticosteroid therapy is not tolerated, consider intravenous corticosteroids as clinically indicated.

Ongoing care requires a multidisciplinary care team 

Even after disease-modifying treatment, patients with SMA may need respiratory, nutritional, and musculoskeletal support. The team will vary from patient to patient, but a coordinated team of specialists can help monitor the patient’s SMA.3,4

It is recommended that a neurological expert, such as a pediatric neurologist or a neuromuscular specialist, coordinate the care of the patient, as they will likely have the most experience with anticipating needs.3,4

While the specific needs and support levels of patients differ, part of the ongoing care can include an assessment of motor function, which may include regular sessions with a physical therapist and possible use of braces. Additionally, nutritionists can be involved to monitor weight and nutrient intake, paying careful attention to calcium and vitamin D for bone health.3

Patient and caregiver support

A resource for caregivers

Help caregivers understand what to expect after treatment and how to maintain proper SMA care. Fill out the Post-Treatment Plan and share it with your patient’s family prior to the patient being discharged.

Post-Treatment Plan

DOWNLOAD

Patient Profiles

Explore the patient profiles and watch family stories

Patient Profiles

References: 1. ZOLGENSMA [prescribing information]. Bannockburn, IL: Novartis Gene Therapies, Inc; 2021. 2. Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3):197-207. 3. Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103-115. 4. Wang CH, Finkel Rs, Bertini ES, et al; Participants of the International Conference on SMA Standard of Care. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027-1048.